Synthego has started work on a 20,000-square-foot manufacturing facility in the USA.
The facility, which will be situated in the San Francisco Bay region, will enable the company to enhance the manufacturing of its gene editing tools by expanding the Halo platform.
Halo™ is a cutting-edge platform that offers top-notch gene editing tools to seamlessly meet your research requirements, from RUO to GMP reagents.
Halo will give Synthego the ability to substantially increase production of its precise gene editing tools, which support a wide range of nucleases, and meet the demands of biopharma clients who are advancing the research and development of CRISPR-mediated gene treatments.
It is expected that the new facility will be operational by the end of 2022.
The manufacturing facility will have 7,000 square feet of cleanroom space and 10,000 square feet of lab space, including special quality control and research and development labs. The facility will have the capability for 24/7 parallel batch production.